Surgical Outcomes After Neoadjuvant Chemoimmunotherapy for Resectable Non-Small Cell Lung Cancer

Surgical Outcomes After Neoadjuvant Chemoimmunotherapy for Resectable Non-Small Cell Lung Cancer

BackgroundNeoadjuvant chemoimmunotherapy for resectable non-small cell lung cancer (NSCLC) represents an important research topic. Despite the potential benefits of this approach, the inflammatory responses and adverse events associated with neoadjuvant chemoimmunotherapy can present technical chall...

Full description

Bibliographic Details
Main Authors:	Yan Hu, Si-Ying Ren, Ruo-Yao Wang, Chao Zeng, Ji-Na Li, Peng Xiao, Fang Wu, Feng-Lei Yu, Wen-Liang Liu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-10-01
Series:	Frontiers in Oncology
Subjects:	neoadjuvant therapy immunotherapy immune checkpoint inhibitors chemoimmunotherapy surgery non-small cell lung cancer
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2021.684070/full

Similar Items

Surgical perspective in neoadjuvant chemoimmunotherapy for stage II–III non‐small cell lung cancer
by: Tao Hong, et al.
Published: (2021-10-01)

A real‐world comparison between neoadjuvant chemoimmunotherapy and chemotherapy alone for resectable non‐small cell lung cancer
by: Baihua Zhang, et al.
Published: (2023-01-01)

The Efficacy and Safety of Neoadjuvant Immunotherapy in Patients with Non-Small Cell Lung Cancer
by: Deniz Can Guven, et al.
Published: (2023-12-01)

Robotic-assisted thoracic surgery following neoadjuvant chemoimmunotherapy in patients with stage III non-small cell lung cancer: A real-world prospective cohort study
by: Yang Gao, et al.
Published: (2022-08-01)

A systematic review and meta-analysis of neoadjuvant chemoimmunotherapy in stage III non-small cell lung cancer
by: Wei Liu, et al.
Published: (2022-12-01)

Clinical factors and major pathological response after neoadjuvant chemoimmunotherapy in potentially resectable lung squamous cell carcinoma
by: Ye Wang, et al.
Published: (2024-04-01)

Neoadjuvant immunotherapy for non–small cell lung cancer: State of the art
by: Jin Kang, et al.
Published: (2021-04-01)

Neoadjuvant immunochemotherapy with pembrolizumab plus chemotherapy in resectable non-small cell lung cancer
by: Yulong Chen, et al.
Published: (2023-09-01)

Neoadjuvant chemoimmunotherapy in locally advanced gastric or gastroesophageal junction adenocarcinoma
by: Xiao Liu, et al.
Published: (2024-04-01)

Neoadjuvant immunotherapy and chemoimmunotherapy for stage II-III muscle invasive bladder cancer
by: Hualin Chen, et al.
Published: (2022-08-01)

Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial
by: Raquel Laza‐Briviesca, et al.
Published: (2021-07-01)

Neoadjuvant chemoimmunotherapy cycle number selection for non-small cell lung cancer and clinical outcomes: a real-world analysis
by: Baihua Zhang, et al.
Published: (2023-09-01)

Deep learning for predicting major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer: A multicentre studyResearch in context
by: Yunlang She, et al.
Published: (2022-12-01)

Complete pathological remission and tertiary lymphoid structures are associated with the efficacy of resectable NSCLC receiving neoadjuvant chemoimmunotherapy: A double-center retrospective study
by: Ying Liu, et al.
Published: (2023-12-01)

Pathologic responses to neoadjuvant chemoimmunotherapy in primary limited‐stage small‐cell lung cancer
by: Meng Lu, et al.
Published: (2022-11-01)

Neoadjuvant chemoimmunotherapy achieved a pathologic complete response in stage IIIA lung adenocarcinoma harboring RET fusion: a case report
by: Minqian Dai, et al.
Published: (2024-01-01)

Non-invasive prediction for pathologic complete response to neoadjuvant chemoimmunotherapy in lung cancer using CT-based deep learning: a multicenter study
by: Wendong Qu, et al.
Published: (2024-03-01)

Safety and feasibility of robotic-assisted thoracic surgery after neoadjuvant chemoimmunotherapy in non-small cell lung cancer
by: Jun Zeng, et al.
Published: (2023-02-01)

Neoadjuvant therapy in non-small cell lung cancer: basis, promise, and challenges
by: Sukumar Kalvapudi, et al.
Published: (2023-12-01)

Application of Neoadjuvant Chemoimmunotherapy in Resectable NSCLC
by: Huaiyong WANG, et al.
Published: (2023-11-01)

A lack of association between BMI and chemoimmunotherapy efficacy in advanced non-small cell lung cancer: Secondary analysis of the IMpower150 and IMpower130 clinical trials
by: Lee X. Li, et al.
Published: (2024-03-01)

Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer. A Narrative Review
by: Lavinia Gatteschi, et al.
Published: (2021-10-01)

Erratum: Safety and feasibility of robotic-assisted thoracic surgery after neoadjuvant chemoimmunotherapy in non-small cell lung cancer
by: Frontiers Production Office
Published: (2023-05-01)

The earlier, the better? A review of neoadjuvant immunotherapy in resectable non‐small‐cell lung cancer
by: Fajiu Li, et al.
Published: (2022-06-01)

Efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy in potentially resectable stage IIIA/IIIB non-small cell lung cancer: Neo-Pre-IC, a single-arm phase 2 trialResearch in context
by: Chao Sun, et al.
Published: (2024-02-01)

Tumor regression rate, PD-L1 expression, pembrolizumab/nab-paclitaxel–based regimens, squamous cell carcinoma, and comorbidities were independently associated with efficacy of neoadjuvant chemoimmunotherapy in non-small cell lung cancer
by: Xingsheng Hu, et al.
Published: (2023-01-01)

Pathologic response and safety to neoadjuvant PD-1 inhibitors and chemotherapy in resectable squamous non-small-cell Lung cancer
by: Liang Shi, et al.
Published: (2022-10-01)

First-line chemoimmunotherapy and immunotherapy in patients with non-small cell lung cancer and brain metastases: a registry study
by: Lauren Julia Brown, et al.
Published: (2024-02-01)

Comparison of neoadjuvant chemoimmunotherapy and chemotherapy alone for resectable stage III non-small cell lung cancer: a real-world cohort study
by: Sihao Zhou, et al.
Published: (2023-12-01)

Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small-Cell Lung Cancer, Past, Present, and Future
by: Chun Ho Szeto, et al.
Published: (2021-11-01)

Progress on Neoadjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer
by: Chang QI, et al.
Published: (2024-02-01)

Exploring the Evolving Scope of Neoadjuvant Immunotherapy in NSCLC
by: John F. Roller, et al.
Published: (2022-01-01)

Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study
by: Kenji Morimoto, et al.
Published: (2021-01-01)

Will neo-adjuvant immunotherapy become a new paradigm in the treatment of lung cancer patients
by: K. K. Laktionov, et al.
Published: (2019-12-01)

Evaluation of the efficacy and surgical-related safety of neoadjuvant immunochemotherapy in advanced resectable none small cell lung cancer (NSCLC)
by: Qin Wang, et al.
Published: (2023-12-01)

Evaluating the potential of immunotherapy and chemoimmunotherapy in the treatment of elderly non-small cell lung cancer patients: A real-world study
by: Satoshi Endo, et al.
Published: (2023-01-01)

Neoadjuvant sintilimab combined with chemotherapy in resectable locally advanced non-small cell lung cancer: case series and literature review
by: Cunli Yin, et al.
Published: (2023-09-01)

Neoadjuvant chemoimmunotherapy as a potential therapeutic option in NSCLC UICC stage IIIA with multilevel N2 disease
by: Hruy Menghesha, et al.
Published: (2022-01-01)

Bevacizumab-Containing Chemoimmunotherapy for Recurrent Non-Small-Cell Lung Cancer after Chemoradiotherapy: Case Report
by: Nobutaka Kataoka, et al.
Published: (2021-05-01)

Multi-scale characterization of tumor-draining lymph nodes in resectable lung cancer treated with neoadjuvant immune checkpoint inhibitors
by: Haitang Yang, et al.
Published: (2022-10-01)